Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous umbilical cord blood mononuclear cells (Mononuclear Therapeutics Limited)
- Development stage
- Unknown
- Lead developer
- Mononuclear Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This autologous umbilical cord blood mononuclear cell therapy is an investigational biologic developed by Mononuclear Therapeutics Ltd. for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE) and neonatal anemia. The therapy involves the collection of a newborn's own umbilical cord blood at birth, which is then processed using the SynGeneX-1000 system to isolate the mononuclear cell fraction. This fraction contains a diverse population of cells, including hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, lymphocytes, and monocytes. Administered intravenously within 48 hours of birth, the therapy aims to mitigate brain injury through neuroprotective, anti-inflammatory, and immunomodulatory effects, while also promoting neural plasticity and addressing anemia. It is currently being evaluated in Phase 1 clinical trials for safety and feasibility.
- Other names
- autologous umbilical cord bloodautologous UCBautologous UCB mononuclear cells
Beyond the preview
Go deeper on autologous umbilical cord blood mononuclear cells (Mononuclear Therapeutics Limited).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous umbilical cord blood mononuclear cells (Mononuclear Therapeutics Limited).